EP2755685A4 - TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES - Google Patents

TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES

Info

Publication number
EP2755685A4
EP2755685A4 EP11872271.9A EP11872271A EP2755685A4 EP 2755685 A4 EP2755685 A4 EP 2755685A4 EP 11872271 A EP11872271 A EP 11872271A EP 2755685 A4 EP2755685 A4 EP 2755685A4
Authority
EP
European Patent Office
Prior art keywords
toll
antagonists
metabolic
receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11872271.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2755685A1 (en
Inventor
Mark Cunningham
Yiqing Feng
Katharine Heeringa
Jinquan Luo
Robert Rauchenberger
Mark Rutz
Mateo Lani San
Robert Sarisky
Vedrana Stojanovic-Susulic
Raymond Sweet
Fang Teng
Alexey Teplyakov
Linda Wu
Sheng-Jiun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of EP2755685A1 publication Critical patent/EP2755685A1/en
Publication of EP2755685A4 publication Critical patent/EP2755685A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11872271.9A 2011-09-12 2011-09-12 TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES Ceased EP2755685A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/051202 WO2013039471A1 (en) 2011-09-12 2011-09-12 Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases

Publications (2)

Publication Number Publication Date
EP2755685A1 EP2755685A1 (en) 2014-07-23
EP2755685A4 true EP2755685A4 (en) 2015-07-01

Family

ID=47883555

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11872271.9A Ceased EP2755685A4 (en) 2011-09-12 2011-09-12 TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES

Country Status (11)

Country Link
EP (1) EP2755685A4 (ja)
JP (1) JP2014526464A (ja)
KR (1) KR20140075708A (ja)
CN (1) CN104159610A (ja)
BR (1) BR112014005786A2 (ja)
CA (1) CA2855955A1 (ja)
EA (1) EA201490623A1 (ja)
IL (1) IL231413A0 (ja)
MX (1) MX362457B (ja)
NZ (1) NZ622260A (ja)
WO (1) WO2013039471A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174704A1 (ja) * 2013-04-22 2014-10-30 国立大学法人東京大学 炎症性疾患の予防又は治療剤
WO2015016282A1 (ja) * 2013-07-30 2015-02-05 国立大学法人東京大学 放射線誘導性消化管症候群の予防又は治療用医薬組成物
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
IL258317B1 (en) 2015-10-02 2024-08-01 Hoffmann La Roche Human anti–CD20/human transferrin receptor bispecific antibodies and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051470A2 (en) * 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists
WO2010127113A2 (en) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
EP2344175B1 (en) * 2008-10-02 2015-07-22 Janssen Biotech, Inc. Methods for suppressing toll-like receptor activity
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051470A2 (en) * 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists
US20100166778A1 (en) * 2008-10-31 2010-07-01 Mark Cunningham Toll-Like Receptor 3 Antagonists
WO2010127113A2 (en) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013039471A1 *

Also Published As

Publication number Publication date
CN104159610A (zh) 2014-11-19
CA2855955A1 (en) 2013-03-21
NZ622260A (en) 2016-11-25
WO2013039471A1 (en) 2013-03-21
KR20140075708A (ko) 2014-06-19
EP2755685A1 (en) 2014-07-23
MX2014002982A (es) 2015-07-06
BR112014005786A2 (pt) 2017-03-28
MX362457B (es) 2019-01-18
JP2014526464A (ja) 2014-10-06
IL231413A0 (en) 2014-04-30
EA201490623A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
EP2900266A4 (en) TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES
EP2773263A4 (en) METABOLIC AND CARDIO-PULMONARY MONITORING DEVICE
ZA201308421B (en) Compositions uses and methods for treatment of metabolic disorders and diseases
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
HK1201454A1 (en) Therapeutic agents and uses thereof
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
ME02180B (me) Supstanca korisna za lečenje poremećaja metabolizma lipida
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EP2755685A4 (en) TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES
EP2841077A4 (en) NUTRITIONAL FIBER COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISORDERS
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
IL234616A0 (en) A herbal preparation for the treatment of metabolic diseases
HK1182712A1 (en) Therapeutic agents 976 976
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
EP2600716A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
GB201019482D0 (en) Compounds for the treatment of metabolic disorders
GB201006164D0 (en) Compounds for the treatment of metabolic disorders
GB201006163D0 (en) Compounds for the treatment of metabolic disorders
GB201004740D0 (en) Compounds for the treatment of metabolic disorders
GB201004744D0 (en) Compounds for the treatment of metabolic disorders
GB201004742D0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140411

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150603

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20150528BHEP

Ipc: C07K 16/28 20060101ALI20150528BHEP

17Q First examination report despatched

Effective date: 20170512

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20191226